Synendos Therapeutics AG develops Selective Endocannabinoid Re-uptake Inhibitors (SERIs) that target the endocannabinoid system to restore normal neurotransmission in the brain. Their lead candidate, SYT-510, aims to address neuropsychiatric disorders characterized by endocannabinoid deficiency, such as post-traumatic stress disorder (PTSD).
Funding
$26M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
YCFounders
Product
Problem
Neuropsychiatric disorders, such as post-traumatic stress disorder (PTSD), are often characterized by an endocannabinoid deficiency, leading to impaired neurotransmission in the brain. Current treatments may not fully address the underlying endocannabinoid system dysfunction.
Solution
Synendos Therapeutics is developing Selective Endocannabinoid Re-uptake Inhibitors (SERIs), a novel class of compounds designed to restore normal neurotransmission in the brain by targeting the endocannabinoid system. Their lead candidate, SYT-510, modulates a newly identified drug target responsible for endocannabinoid cell reuptake, exerting pro-homeostatic effects on neuronal circuits through a self-limiting mechanism. This approach aims to provide safer and more effective therapies for central nervous system (CNS) disorders characterized by endocannabinoid deficiency. By modulating the endocannabinoid system, Synendos seeks to address the root cause of these disorders and improve patient outcomes.
Target Audience
The primary target audience includes individuals suffering from neuropsychiatric disorders characterized by endocannabinoid deficiency, such as post-traumatic stress disorder (PTSD), and the clinicians who treat them.
Features
- SYT-510: A first-in-class Selective Endocannabinoid Re-uptake Inhibitor (SERI)
- Modulation of endocannabinoid cell reuptake, a newly identified drug target
- Self-limiting mechanism of action for enhanced safety and efficacy
- Potential to restore normal endocannabinoid tone in the brain
- Preclinical and clinical development of SYT-510 and follow-up compounds
- Robust patent protection for assets and targets in major markets